Nanoform Finland Plc, Interim Report January - September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time
COMPANY RELEASE Nanoform Finland Plc, Interim Report January - September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, one more non-GMP line commissioned and a new near-term business target introduced: “First Biologics PoC project in 2021”. 7-9/2020 key financials: - Revenue was EUR 159 thousand, during 7-9/2019